Key result
PlmCas12e CCR5 cleavage varies by target site, spacer length, and PAM purine preference.
Why the study?
To determine optimal conditions for PlmCas12e cleavage of the cellular gene CCR5 by investigating the impact of guide RNA spacer length and alternative PAM sequences on cleavage activity.
Optimizing guide RNA spacer length and PAM sequence improves PlmCas12e (CasX2) cleavage of CCR5, facilitating therapeutic strategies for HIV-1 resistance.
Supports PlmCas12e optimization for CCR5 editing in models; leaves open clinical translation for HIV-1 resistance.
Gene editing using CRISPR/Cas (clustered regularly interspaced palindromic repeats/CRISPR-associated) is under development as a therapeutic tool for the modification of genes in eukaryotic cells. While much effort has focused on CRISPR/Cas9 systems from Streptococcus pyogenes and Staphylococcus aureus, alternative CRISPR systems have been identified from non-pathogenic microbes, including previously unknown class 2 systems, adding to a diverse toolbox of CRISPR/Cas enzymes. The Cas12e enzymes from non-pathogenic Deltaproteobacteria (CasX1, DpeCas12e) and Planctomycetes (CasX2, PlmCas12e) are smaller than Cas9, have a selective protospacer adjacent motif (PAM), and deliver a staggered cleavage cut with a 5–7 nucleotide overhang. We investigated the impact of guide RNA spacer length and alternative PAM sequences on cleavage activity to determine optimal conditions for PlmCas12e cleavage of the cellular gene CCR5 (CC-Chemokine receptor-5). CCR5 encodes the CCR5 coreceptor used by human immunodeficiency virus-type 1 (HIV-1) to infect target cells. A 32 base-pair deletion in CCR5 (CCR5-Δ32) is responsible for HIV-1 resistance and reported cures following bone marrow transplantation. Consequently, CCR5 has been an important target for gene editing utilizing CRISPR/Cas. We determined that CCR5 cleavage activity varied with the target site, spacer length, and the fourth nucleotide in the previously described PAM sequence, TTCN. Our analyses demonstrated a PAM preference for purines (adenine, guanine) over pyrimidines (thymidine, cytosine) in the fourth position of the CasX2 PAM. This improved understanding of CasX2 cleavage requirements facilitates the development of therapeutic strategies to recreate the CCR5-Δ32 mutation in haematopoietic stem cells.
No takes yet. Share an insight, caveat, or question.
Armstrong et al. (2023) studied HIV-1 resistance / CCR5 gene editing. PlmCas12e (CasX2) cleavage of CCR5 was evaluated on CCR5 cleavage activity. PlmCas12e (CasX2) cleavage activity of CCR5 varied with target site, spacer length, and showed a PAM preference for purines over pyrimidines in the fourth position.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: